Drugs Made In America Acquisition II Corp. (DMII) Form 10-Q — May 14, 2026
Drugs Made In America Acquisition II Corp. reported a net income of $4.34 million for the quarter ended March 31, 2026, driven primarily by $4.44 million in interest earned on its trust account, offset by $132,000 in operating expenses. The filing reveals significant governance and liquidity red flags, including a material weakness in internal controls due to inadequate segregation of duties and a lack of formal review processes for related-party transactions.
Key figures
- Net Income
- 4337820
- Total Debt
- 450000
- Cash Position
- 347720
- Bridge Note Amount
- 450000
- Shares Outstanding
- 63700000
- Sponsor Withdrawal
- 1345844
- Trust Account Balance
- 509373650
- Sponsor Unpaid Balance
- 782113
- Working Capital Deficit
- 314524
Price after filing
1 day: 0.0%7 days: +0.2%30 days: +0.5%
Close on the filing date to close N calendar days later (from $10.03). Historical, not a forecast.
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.